ANI Pharmaceuticals, Inc. (ANIP)Director sold ~$4.21M

~$4.21M

Approx. value · 47K sh @ $89.48

585K

Holds after · shares reported

Traded

Aug 14, 2025

Filed

Aug 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 13, 2025InsiderOfficer sold ~$25K of ANIP shares in the open market
2. Jul 14, 2025InsiderOfficer sold ~$26K of ANIP shares in the open market
3. Aug 12, 2025Insider · 5 peopleInsiders: 5 sales (~$11.8M)
4. Aug 13, 2025InsiderOfficer sold ~$36K of ANIP shares in the open market
5. Aug 14, 2025 · this disclosureInsiderDirector sold ~$4.21M of ANIP shares in the open market

What came next

1. Aug 15, 2025Insider · 3 peopleInsiders: 3 sales (~$7.2M)
2. Aug 18, 2025Insider · 2 peopleInsiders: 3 sales (~$2.5M)
3. Aug 20, 2025Insider · 2 peopleInsiders: 2 sales (~$4.7M)
4. Aug 21, 2025InsiderDirector sold ~$4.79M of ANIP shares in the open market
5. Aug 22, 2025InsiderOfficer sold ~$161K of ANIP shares in the open market
6. Aug 25, 2025InsiderDirector sold ~$229K of ANIP shares in the open market
7. Sep 3, 2025InsiderDirector sold ~$692K of ANIP shares in the open market
8. Sep 8, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
9. Sep 12, 2025InsiderOfficer sold ~$39K of ANIP shares in the open market
10. Sep 19, 2025InsiderOfficer sold ~$98K of ANIP shares in the open market
11. Sep 26, 2025Company filing · Form 8-K · Unregistered shares, Shareholder rightsSold new shares without registering them, and changed the rights of its shareholders
12. Nov 7, 2025Company filing · Form 8-K · ResultsReported its results
13. Nov 10, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
14. Nov 24, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 24, 2025, Patrick D. Walsh notified the Company that he will not seek re-election as a director at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), but will continue to serve as a director until the Annual Meeting.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for ANI Pharmaceuticals, Inc.

For ANI Pharmaceuticals, Inc., OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANIP page.

Other recent filings by Muthusamy Shanmugam, HEAD OF R&D, COO-NOVITIUM OPS

• SEC Form 4 at ANI Pharmaceuticals, Inc. (ANIP)Aug 22, 2025
• SEC Form 4 at ANI Pharmaceuticals, Inc. (ANIP)Aug 22, 2025
• SEC Form 4 at ANI Pharmaceuticals, Inc. (ANIP)Aug 18, 2025
• SEC Form 4 at ANI Pharmaceuticals, Inc. (ANIP)May 13, 2025

The full history of Muthusamy Shanmugam, HEAD OF R&D, COO-NOVITIUM OPS is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at ANI Pharmaceuticals, Inc.

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 14, 2026
• SEC Form 13F-HRMay 13, 2026

Everything OQRO holds on this company is on its ANIP page.